Can a common chemo drug be matched to tumor genetics?

NCT ID NCT03096418

Recruiting now Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study gives paclitaxel (Taxol) to 50 women with breast cancer before surgery to see if tumors with high chromosomal instability respond better. Researchers will measure tumor shrinkage and drug levels in the tumor. The goal is to find biomarkers that predict who benefits most from this chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paclitaxel (Taxol)
What this could lead to: If successful, this could help doctors predict which breast cancer patients will benefit most from paclitaxel before surgery, personalizing treatment.
What could go wrong: This is a small, early-phase study focused on biomarkers, not a treatment trial. Results may not change practice or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASM FEMALE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of Iowa Health Care/Holden Comprehensive Cancer Center
RECRUITING

Iowa City, Iowa, 52242, United States
University of Wisconsin Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.